A total of 144 patients were recruited for this randomized, double-blind study to compare the efficacy and tolerance of tenoxicam and sustained release indomethacin in patients with osteoarthritis. The results show that 20 mg/day tenoxicam is equal in efficacy to, and significantly better tolerated than, 75 mg/day sustained release indomethacin. Patients receiving tenoxicam recorded significantly better global tolerance ratings (P=0.042) and fewer adverse events than those receiving indomethacin.
HeintzRCGuentertTWEnricoJF: Pharmacokinetics of tenoxicam in healthy human volunteers. Eur J Rheum Inflamm1984; 7: 33–44.
2.
CrevoisierCHeizmannP: Pharmacokinetics of tenoxicam. EULAR Lit Rheum1986; 5: 7–14.
3.
JensenEMAndersenRBFossgreenJ: A randomized double blind long term trial comparing tenoxicam and piroxicam in osteoarthritis of the hip or knee. Curr Ther Res1986; 39: 365–377.
4.
ScholzHJAdamczykAHäringerE: Behandlung der chronischen Polyarthritis und degenerativer Gelenkerkrankungen: Multizentrische Doppelblindstudie Tenoxicam versus Piroxicam. MMW1988; 130: 94–96.
5.
HonoratoJCuenaRArzanzaJR: Ensayo clinico, paralelo, doble ciego con el tenoxicam frente a indometacina en el tratamiento de artritis reumatoide. Rev Med Univ Navarra1984; 28: 49–53.
6.
TorisuTNobunagaTIwasakiY: Evaluation of efficacy of tenoxicam on chronic rheumatoid arthritis. Ryumachi1984; 24: 295–308.
7.
WilleT: Treatment of osteoarthritis with tenoxicam—a double blind comparison with indomethacin. Presented at the EULAR Symposium, Rome, October 1986.
8.
ADIS Press Editorial Development: Tenoxicam in Perspective.Manchester: ADIS Press, 1987.
